loading
前日終値:
$87.81
開ける:
$88.1
24時間の取引高:
388.63K
Relative Volume:
0.54
時価総額:
$5.55B
収益:
$136.86M
当期純損益:
$-168.69M
株価収益率:
-31.06
EPS:
-2.81
ネットキャッシュフロー:
$-113.49M
1週間 パフォーマンス:
-3.76%
1か月 パフォーマンス:
+37.09%
6か月 パフォーマンス:
+51.04%
1年 パフォーマンス:
+76.95%
1日の値動き範囲:
Value
$86.75
$88.36
1週間の範囲:
Value
$86.75
$91.39
52週間の値動き範囲:
Value
$40.61
$94.80

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
名前
Rhythm Pharmaceuticals Inc
Name
セクター
Healthcare (1161)
Name
電話
857-264-4280
Name
住所
222 BERKELEY STREET, BOSTON, MA
Name
職員
283
Name
Twitter
@rhythmpharma
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
RYTM's Discussions on Twitter

RYTM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
87.27 5.79B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-10 開始されました Goldman Buy
2025-07-07 開始されました Leerink Partners Outperform
2025-04-07 アップグレード BofA Securities Neutral → Buy
2025-03-05 再開されました Stifel Buy
2025-01-02 開始されました Jefferies Buy
2024-12-20 開始されました Oppenheimer Outperform
2024-10-21 開始されました Guggenheim Buy
2024-09-18 開始されました H.C. Wainwright Buy
2024-09-17 開始されました JMP Securities Mkt Outperform
2024-05-08 ダウングレード BofA Securities Buy → Neutral
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-08-01 アップグレード BofA Securities Neutral → Buy
2023-01-18 再開されました Canaccord Genuity Buy
2022-08-08 アップグレード Goldman Neutral → Buy
2022-08-05 アップグレード BofA Securities Underperform → Neutral
2022-06-17 繰り返されました Needham Buy
2022-03-02 再開されました Stifel Buy
2022-02-17 アップグレード Ladenburg Thalmann Neutral → Buy
2021-12-08 開始されました Wells Fargo Overweight
2021-11-19 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-14 再開されました Goldman Neutral
2021-08-04 ダウングレード BofA Securities Neutral → Underperform
2021-08-04 ダウングレード Ladenburg Thalmann Buy → Neutral
2020-11-30 ダウングレード BofA Securities Buy → Neutral
2020-01-08 開始されました Goldman Sell
2019-07-12 アップグレード Stifel Hold → Buy
2019-07-08 開始されました Canaccord Genuity Buy
2019-03-13 開始されました Ladenburg Thalmann Buy
2018-09-07 再開されました Morgan Stanley Overweight
2018-06-25 繰り返されました Needham Buy
2018-06-15 繰り返されました Needham Buy
2017-10-30 開始されました BofA/Merrill Buy
2017-10-30 開始されました Needham Buy
すべてを表示

Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース

pulisher
Jul 24, 2025

Is Rhythm Pharmaceuticals Inc. a good long term investmentDouble-digit growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastHigh-yield growth strategies - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

What drives Rhythm Pharmaceuticals Inc. stock priceExplosive returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool

Jul 21, 2025
pulisher
Jul 20, 2025

Rhythm Pharmaceuticals prices $175M stock offering - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq

Jul 18, 2025
pulisher
Jul 18, 2025

Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

(RYTM) Investment Analysis - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 15, 2025

Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada

Jul 15, 2025
pulisher
Jul 13, 2025

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals announces public offering of common stock - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN

Jul 13, 2025
pulisher
Jul 13, 2025

Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN

Jul 12, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Explores New Treatment for Hypotha - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals' Bivamelagon: A Path to Dominating Acquired Hypothalamic Obesity and Driving Stock Gains - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Gets Price Target Boost from Oppen - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals prices upsized public offering at $85 per share - Investing.com India

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by B of A Secu - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com

Jul 10, 2025
pulisher
Jul 10, 2025

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - The Globe and Mail

Jul 10, 2025
pulisher
Jul 10, 2025

Oppenheimer raises Rhythm Pharmaceuticals stock price target to $110 By Investing.com - Investing.com Canada

Jul 10, 2025

Rhythm Pharmaceuticals Inc (RYTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
大文字化:     |  ボリューム (24 時間):